KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Change in Accured Expenses: 2010-2025

Historic Change in Accured Expenses for Emergent BioSolutions (EBS) over the last 16 years, with Sep 2025 value amounting to $1.3 million.

  • Emergent BioSolutions' Change in Accured Expenses fell 96.74% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$78.1 million, marking a year-over-year decrease of 1155.41%. This contributed to the annual value of -$18.2 million for FY2024, which is 67.32% up from last year.
  • As of Q3 2025, Emergent BioSolutions' Change in Accured Expenses stood at $1.3 million, which was down 66.67% from $3.9 million recorded in Q2 2025.
  • Emergent BioSolutions' 5-year Change in Accured Expenses high stood at $39.9 million for Q3 2024, and its period low was -$51.1 million during Q4 2024.
  • Its 3-year average for Change in Accured Expenses is -$9.2 million, with a median of -$16.4 million in 2023.
  • In the last 5 years, Emergent BioSolutions' Change in Accured Expenses soared by 443.81% in 2021 and then tumbled by 281.19% in 2022.
  • Emergent BioSolutions' Change in Accured Expenses (Quarterly) stood at $10.1 million in 2021, then slumped by 281.19% to -$18.3 million in 2022, then plummeted by 39.34% to -$25.5 million in 2023, then plummeted by 100.39% to -$51.1 million in 2024, then plummeted by 96.74% to $1.3 million in 2025.
  • Its Change in Accured Expenses stands at $1.3 million for Q3 2025, versus $3.9 million for Q2 2025 and -$32.2 million for Q1 2025.